Loading…
Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra
Saved in:
Published in: | Rheumatology (Oxford, England) England), 2021-11, Vol.60 (11), p.e375-e377 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723 |
---|---|
cites | cdi_FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723 |
container_end_page | e377 |
container_issue | 11 |
container_start_page | e375 |
container_title | Rheumatology (Oxford, England) |
container_volume | 60 |
creator | Calvo-Aranda, Enrique Sanchez-Aranda, Fernando Manuel |
description | |
doi_str_mv | 10.1093/rheumatology/keab383 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2528908175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528908175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EoqXwBwh5ySbUjyROlqgqD6kSG1iwihxn3JomcfEDFL6eoBbEamYxZ-7MQeiSkhtKSj53G4idDLa162G-BVnzgh-hKU1zlhDO2fFfz9IJOvP-jRCSUV6coglPCSlZSqfodam1UVIN2GrsY61ikD3Y6HGwyrTma8yosemxxDsZDPQBf5qwwR4-wAFe2xiwA-2kCtYNI4RlL7emd_IcnWjZerg41Bl6uVs-Lx6S1dP94-J2lShOREiyusiZ5AVluSCZKBuhGElBATTAgOmGNLyWRKQlY7LJhCh1QYXWpYa8qQXjM3S937tz9j2CD1VnvIK23f9RsYwVJRmZbBxN96PKWe_Hs6udM510Q0VJ9SO1-i-1OkgdsatDQqw7aP6gX4v8GyR-eac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528908175</pqid></control><display><type>article</type><title>Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Calvo-Aranda, Enrique ; Sanchez-Aranda, Fernando Manuel</creator><creatorcontrib>Calvo-Aranda, Enrique ; Sanchez-Aranda, Fernando Manuel</creatorcontrib><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab383</identifier><identifier>PMID: 34009241</identifier><language>eng</language><publisher>England</publisher><subject><![CDATA[Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - adverse effects ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - classification ; Drug Resistance - drug effects ; Drug Resistance - immunology ; Drug Therapy, Combination - methods ; Gout - blood ; Gout - drug therapy ; Gout - physiopathology ; Humans ; Injections, Subcutaneous ; Interleukin 1 Receptor Antagonist Protein - administration & dosage ; Interleukin 1 Receptor Antagonist Protein - adverse effects ; Male ; Middle Aged ; Patient Acuity ; Receptors, Interleukin-1 - antagonists & inhibitors ; Receptors, Interleukin-6 - antagonists & inhibitors ; Severity of Illness Index ; Treatment Outcome ; Uric Acid - blood]]></subject><ispartof>Rheumatology (Oxford, England), 2021-11, Vol.60 (11), p.e375-e377</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723</citedby><cites>FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723</cites><orcidid>0000-0002-3095-0969</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34009241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calvo-Aranda, Enrique</creatorcontrib><creatorcontrib>Sanchez-Aranda, Fernando Manuel</creatorcontrib><title>Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - classification</subject><subject>Drug Resistance - drug effects</subject><subject>Drug Resistance - immunology</subject><subject>Drug Therapy, Combination - methods</subject><subject>Gout - blood</subject><subject>Gout - drug therapy</subject><subject>Gout - physiopathology</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin 1 Receptor Antagonist Protein - administration & dosage</subject><subject>Interleukin 1 Receptor Antagonist Protein - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Acuity</subject><subject>Receptors, Interleukin-1 - antagonists & inhibitors</subject><subject>Receptors, Interleukin-6 - antagonists & inhibitors</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Uric Acid - blood</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRS0EoqXwBwh5ySbUjyROlqgqD6kSG1iwihxn3JomcfEDFL6eoBbEamYxZ-7MQeiSkhtKSj53G4idDLa162G-BVnzgh-hKU1zlhDO2fFfz9IJOvP-jRCSUV6coglPCSlZSqfodam1UVIN2GrsY61ikD3Y6HGwyrTma8yosemxxDsZDPQBf5qwwR4-wAFe2xiwA-2kCtYNI4RlL7emd_IcnWjZerg41Bl6uVs-Lx6S1dP94-J2lShOREiyusiZ5AVluSCZKBuhGElBATTAgOmGNLyWRKQlY7LJhCh1QYXWpYa8qQXjM3S937tz9j2CD1VnvIK23f9RsYwVJRmZbBxN96PKWe_Hs6udM510Q0VJ9SO1-i-1OkgdsatDQqw7aP6gX4v8GyR-eac</recordid><startdate>20211103</startdate><enddate>20211103</enddate><creator>Calvo-Aranda, Enrique</creator><creator>Sanchez-Aranda, Fernando Manuel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3095-0969</orcidid></search><sort><creationdate>20211103</creationdate><title>Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra</title><author>Calvo-Aranda, Enrique ; Sanchez-Aranda, Fernando Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - classification</topic><topic>Drug Resistance - drug effects</topic><topic>Drug Resistance - immunology</topic><topic>Drug Therapy, Combination - methods</topic><topic>Gout - blood</topic><topic>Gout - drug therapy</topic><topic>Gout - physiopathology</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin 1 Receptor Antagonist Protein - administration & dosage</topic><topic>Interleukin 1 Receptor Antagonist Protein - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Acuity</topic><topic>Receptors, Interleukin-1 - antagonists & inhibitors</topic><topic>Receptors, Interleukin-6 - antagonists & inhibitors</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Uric Acid - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calvo-Aranda, Enrique</creatorcontrib><creatorcontrib>Sanchez-Aranda, Fernando Manuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calvo-Aranda, Enrique</au><au>Sanchez-Aranda, Fernando Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2021-11-03</date><risdate>2021</risdate><volume>60</volume><issue>11</issue><spage>e375</spage><epage>e377</epage><pages>e375-e377</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><cop>England</cop><pmid>34009241</pmid><doi>10.1093/rheumatology/keab383</doi><orcidid>https://orcid.org/0000-0002-3095-0969</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | Rheumatology (Oxford, England), 2021-11, Vol.60 (11), p.e375-e377 |
issn | 1462-0324 1462-0332 |
language | eng |
recordid | cdi_proquest_miscellaneous_2528908175 |
source | Oxford Journals Online; Alma/SFX Local Collection |
subjects | Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - classification Drug Resistance - drug effects Drug Resistance - immunology Drug Therapy, Combination - methods Gout - blood Gout - drug therapy Gout - physiopathology Humans Injections, Subcutaneous Interleukin 1 Receptor Antagonist Protein - administration & dosage Interleukin 1 Receptor Antagonist Protein - adverse effects Male Middle Aged Patient Acuity Receptors, Interleukin-1 - antagonists & inhibitors Receptors, Interleukin-6 - antagonists & inhibitors Severity of Illness Index Treatment Outcome Uric Acid - blood |
title | Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20subcutaneous%20tocilizumab%20in%20a%20patient%20with%20severe%20gout%20refractory%20to%20anakinra&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Calvo-Aranda,%20Enrique&rft.date=2021-11-03&rft.volume=60&rft.issue=11&rft.spage=e375&rft.epage=e377&rft.pages=e375-e377&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab383&rft_dat=%3Cproquest_cross%3E2528908175%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c307t-5b862a3812670579d7c204eceede2e2fd0d3ba074922ad5779f817ff9fe6db723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2528908175&rft_id=info:pmid/34009241&rfr_iscdi=true |